[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565849":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":60,"collaborators":63,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":26,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Yale University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"THC then Placebo","EXPERIMENTAL","Participants in this arm will receive THC then placebo in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive THC in the first session will receive placebo at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.",[13,14],"Drug: THC","Drug: Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo then THC","PLACEBO_COMPARATOR","Participants in this arm will receive placebo then THC in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design. (Participants randomized to receive placebo in the first session will receive THC at the 2nd session.) Sessions will be scheduled at least one week apart. Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI.",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","THC","Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)",[16,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Participants will be administered identical plant material from which all THC has been removed by solvent extraction.",[16,9],[32],{"name":33,"affiliation":34,"role":35},"Godfrey Pearlson, M.D","Founding Director, Olin Neuropsychiatry Center; Yale University","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Godfrey Pearlson, MD","CONTACT","860-305-8921","godfrey.pearlson@yale.edu",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Ariana Caruso","ariana.caruso2@hhchealth.org",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":26},"Olin Neuropsychiatric Research Center at Hartford Healthcare","RECRUITING","Hartford","Connecticut","06106","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-72.68509,41.76371,{"lat":58,"lon":57},{"type":35,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Godfrey Pearlson","Professor of Psychiatry and of Neuroscience",[64,67],{"name":65,"class":66},"Biopharmaceutical Research Company","INDUSTRY",{"name":68,"class":69},"Bloom Labs Cannabis Solutions","UNKNOWN","100565849","phase-2-pilot-fmri-studies-of-aging-related-effects-of-thc-100565849",false,"NCT06647524","Pilot fMRI Studies of Aging-Related Effects of THC","Inclusion Criteria:\n\n* CNB use within past 2 years and felt \"high\" when used.\n* Able to read, speak, and understand English.\n* Able and willing to provide written informed consent, and willing to commit to the study protocol.\n\nExclusion Criteria:\n\n* Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence.\n* Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment\n* History of adverse effects with CNB\n* CNB users who are abstaining\n* IQ \\\u003C80 on the Wechsler Abbreviated Scale of Intelligence\n* Inability to comprehend written instructions using the WRAT 4 reading achievement test\n* Pregnant, breastfeeding, and ineffective birth control methods\n* Unable or unsafe to have an MRI\n* Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy\n* History of head trauma with loss of consciousness \\> 30 minutes or concussion lasting 30 days\n* Focal brain lesion seen on structural MRI\n* Any medical\u002Fneurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome)\n* Anyone deemed unsafe to study personnel for any reason\n* Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study\n* Significant pain and\u002For reduced mobility in the arms","ALL","18 Years","75 Years",{"count":80,"type":81},10,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.",[23],[88,89],"Memory Impairment","Learning Impairment","2025-10-06",{"date":92,"type":93},"2025-10-09","ACTUAL",{"date":95,"type":93},"2025-07-01",{"date":97,"type":81},"2027-12",{"name":5,"class":6},1]